The Influence of Biomarker Mutations and Systemic Treatment on Cerebral Metastases from NSCLC Treated with Radiosurgery |
Lee, Min Ho
(Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Kong, Doo-Sik (Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine) Seol, Ho Jun (Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine) Nam, Do-Hyun (Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine) Lee, Jung-Il (Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine) |
1 | Harris S, Chan MD, Lovato JF, Ellis TL, Tatter SB, Bourland JD, et al. : Gamma knife stereotactic radiosurgery as salvage therapy after failure of whole-brain radiotherapy in patients with small-cell lung cancer. Int J Radiat Oncol Biol Phys 83 : e53-59, 2012 DOI |
2 | Johnson AG, Ruiz J, Hughes R, Page BR, Isom S, Lucas JT, et al. : Impact of systemic targeted agents on the clinical outcomes of patients with brain metastases. Oncotarget 6 : 18945-18955, 2015 |
3 | Karampeazis A, Voutsina A, Souglakos J, Kentepozidis N, Giassas S, Christofillakis C, et al. : Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 study. Cancer 119 : 2754-2764, 2013 DOI |
4 | Knights EM Jr : Metastatic tumors of the brain and their relation to primary and secondary pulmonary cancer. Cancer 7 : 259-265, 1954 DOI |
5 | Lee HY, Ahn HK, Jeong JY, Kwon MJ, Han JH, Sun JM, et al. : Favorable clinical outcomes of pemetrexed treatment in anaplastic lymphoma kinase positive non-small-cell lung cancer. Lung Cancer 79 : 40-45, 2013 DOI |
6 | Lee S, Kim Y, Sun JM, Choi YL, Kim JG, Shim YM, et al. : Molecular profiles of EGFR, K-ras, c-met, and FGFR in pulmonary pleomorphic carcinoma, a rare lung malignancy. J Cancer Res Clin Oncol 137 : 1203-1211, 2011 DOI |
7 | Likhacheva A, Pinnix CC, Parikh NR, Allen PK, McAleer MF, Chiu MS, et al. : Predictors of survival in contemporary practice after initial radiosurgery for brain metastases. Int J Radiat Oncol Biol Phys 85 : 656-661, 2013 DOI |
8 | Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. : Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361 : 947-957, 2009 DOI |
9 | Newman SJ, Hansen HH: Proceedings: Frequency, diagnosis, and treatment of brain metastases in 247 consecutive patients with bronchogenic carcinoma. Cancer 33 : 492-496, 1974 DOI |
10 | Ahn HK, Jeon K, Yoo H, Han B, Lee SJ, Park H, et al. : Successful treatment with crizotinib in mechanically ventilated patients with ALK positive non-small-cell lung cancer. J Thorac Oncol 8 : 250-253, 2013 DOI |
11 | Alexander E 3rd, Moriarty TM, Davis RB, Wen PY, Fine HA, Black PM, et al. : Stereotactic radiosurgery for the definitive, noninvasive treatment of brain metastases. J Natl Cancer Inst 87 : 34-40, 1995 DOI |
12 | Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC, et al. : Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 363 : 1665-1672, 2004 DOI |
13 | Baschnagel AM, Meyer KD, Chen PY, Krauss DJ, Olson RE, Pieper DR, et al. : Tumor volume as a predictor of survival and local control in patients with brain metastases treated with gamma knife surgery. J Neurosurg 119 : 1139-1144, 2013 DOI |
14 | Bhatnagar AK, Flickinger JC, Kondziolka D, Lunsford LD : Stereotactic radiosurgery for four or more intracranial metastases. Int J Radiat Oncol Biol Phys 64 : 898-903, 2006 DOI |
15 | Bianco C, Tortora G, Bianco R, Caputo R, Veneziani BM, Caputo R, et al. : Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). Clin Cancer Res 8 : 3250-3258, 2002 |
16 | Billing PS, Miller DL, Allen MS, Deschamps C, Trastek VF, Pairolero PC : Surgical treatment of primary lung cancer with synchronous brain metastases. J Thorac Cardiovasc Surg 122 : 548-553, 2001 DOI |
17 | Cho KR, Lee MH, Kong DS, Seol HJ, Nam DH, Sun JM, et al. : Outcome of gamma knife radiosurgery for metastatic brain tumors derived from non-small cell lung cancer. J Neurooncol 125 : 331-338, 2015 DOI |
18 | Bonnette P, Puyo P, Gabriel C, Giudicelli R, Regnard JF, Riquet M, et al. : Surgical management of non-small cell lung cancer with synchronous brain metastases. Chest 119 : 1469-1475, 2001 DOI |
19 | Chidel MA, Suh JH, Greskovich JF, Kupelian PA, Barnett GH : Treatment outcome for patients with primary nonsmall-cell lung cancer and synchronous brain metastasis. Radiat Oncol Investig 7 : 313-319, 1999 DOI |
20 | Chinnaiyan P, Huang S, Vallabhaneni G, Armstrong E, Varambally S, Tomlins SA, et al. : Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res 65 : 3328-3335, 2005 DOI |
21 | Choi YL, Sun JM, Cho J, Rampal S, Han J, Parasuraman B, et al. : EGFR mutation testing in patients with advanced non-small cell lung cancer: a comprehensive evaluation of real-world practice in an East Asian tertiary hospital. PLoS One 8 : e56011, 2013 DOI |
22 | Cochran DC, Chan MD, Aklilu M, Lovato JF, Alphonse NK, Bourland JD, et al. : The effect of targeted agents on outcomes in patients with brain metastases from renal cell carcinoma treated with Gamma Knife surgery. J Neurosurg 116 : 978-983, 2012 DOI |
23 | Cortot AB, Italiano A, Burel-Vandenbos F, Martel-Planche G, Hainaut P : KRAS mutation status in primary nonsmall cell lung cancer and matched metastases. Cancer 116 : 2682-2687, 2010 DOI |
24 | Galluzzi S, Payne PM : Brain metastases from primary bronchial carcinoma: a statistical study of 741 necropsies. Br J Cancer 10 : 408-414, 1956 DOI |
25 | Schouten LJ, Rutten J, Huveneers HA, Twijnstra A : Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 94 : 2698-2705, 2002 DOI |
26 | Luo D, Ye X, Hu Z, Peng K, Song Y, Yin X, et al. : EGFR mutation status and its impact on survival of Chinese non-small cell lung cancer patients with brain metastases. Tumour Biol 35 : 2437-2444, 2014 DOI |
27 | Noordijk EM, Vecht CJ, Haaxma-Reiche H, Padberg GW, Voormolen JH, Hoekstra FH, et al. : The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age. Int J Radiat Oncol Biol Phys 29 : 711-717, 1994 DOI |
28 | Nose N, Sugio K, Oyama T, Nozoe T, Uramoto H, Iwata T, et al. : Association between estrogen receptor-beta expression and epidermal growth factor receptor mutation in the postoperative prognosis of adenocarcinoma of the lung. J Clin Oncol 27 : 411-417, 2009 DOI |
29 | Patchell RA, Tibbs PA, Walsh JW, Dempsey RJ, Maruyama Y, Kryscio RJ, et al. : A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 322 : 494-500, 1990 DOI |
30 | Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. : Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13 : 239-246, 2012 DOI |
31 | Zhuang HQ, Sun J, Yuan ZY, Wang J, Zhao LJ, Wang P, et al. : Radiosensitizing effects of gefitinib at different administration times in vitro. Cancer Sci 100 : 1520-1525, 2009 DOI |
32 | Sun M, Behrens C, Feng L, Ozburn N, Tang X, Yin G, et al. : HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumors. Clin Cancer Res 15 : 4829-4837, 2009 DOI |
33 | Yamamoto M, Serizawa T, Shuto T, Akabane A, Higuchi Y, Kawagishi J, et al. : Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. Lancet Oncol 15 : 387-395, 2014 DOI |
34 | Zhuang H, Wang J, Zhao L, Yuan Z, Wang P : The theoretical foundation and research progress for WBRT combined with erlotinib for the treatment of multiple brain metastases in patients with lung adenocarcinoma. Int J Cancer 133 : 2277-2283, 2013 DOI |
35 | Matsumoto S, Takahashi K, Iwakawa R, Matsuno Y, Nakanishi Y, Kohno T, et al. : Frequent EGFR mutations in brain metastases of lung adenocarcinoma. Int J Cancer 119 : 1491-1494, 2006 DOI |
36 | Luo S, Chen L, Chen X, Xie X : Evaluation on efficacy and safety of tyrosine kinase inhibitors plus radiotherapy in NSCLC patients with brain metastases. Oncotarget 6 : 16725-16734, 2015 |
37 | Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. : Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362 : 2380-2388, 2010 DOI |
38 | Magilligan DJ Jr, Duvernoy C, Malik G, Lewis JW Jr, Knighton R, Ausman JI : Surgical approach to lung cancer with solitary cerebral metastasis: twenty-five years' experience. Ann Thorac Surg 42 : 360-364, 1986 DOI |
39 | Mekhail T, Sombeck M, Sollaccio R : Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. Curr Oncol Rep 13 : 255-258, 2011 DOI |
40 | Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al. : Gefitinib versus cisplatin plus docetaxel in patients with non-smallcell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11 : 121-128, 2010 DOI |
41 | Sperduto PW, Wang M, Robins HI, Schell MC, Werner-Wasik M, Komaki R, et al. : A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320. Int J Radiat Oncol Biol Phys 85 : 1312-1318, 2013 DOI |
42 | Sorensen JB, Hansen HH, Hansen M, Dombernowsky P : Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis. J Clin Oncol 6 : 1474-1480, 1988 DOI |